临床药物遗传学实施联盟（CPIC）关于 RYR1 或 CACNA1S 基因型背景下使用强效挥发性麻醉剂和琥珀酰胆碱的指南。
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes.
机构信息
Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
Department of Pharmacology & Physiology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
出版信息
Clin Pharmacol Ther. 2019 Jun;105(6):1338-1344. doi: 10.1002/cpt.1319. Epub 2019 Jan 24.
Abstract
The identification in a patient of 1 of the 50 variants in the RYR1 or CACNA1S genes reviewed here should lead to a presumption of malignant hyperthermia susceptibility (MHS). MHS can lead to life-threatening reactions to potent volatile anesthetic agents or succinylcholine. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of these agents in patients with these RYR1 or CACNA1S variants (updates at https://cpicpgx.org/guidelines and www.pharmgkb.org).
摘要
如果在患者中鉴定出这里所回顾的 RYR1 或 CACNA1S 基因中的 50 种变体之一，应推定该患者具有恶性高热易感性（MHS）。MHS 可导致对强效挥发性麻醉剂或琥珀酰胆碱产生危及生命的反应。我们总结了文献中的证据，以支持这种关联，并为在具有这些 RYR1 或 CACNA1S 变体的患者中使用这些药物提供治疗建议（更新网址为 https://cpicpgx.org/guidelines 和 www.pharmgkb.org）。
相似文献
1
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes.临床药物遗传学实施联盟（CPIC）关于 RYR1 或 CACNA1S 基因型背景下使用强效挥发性麻醉剂和琥珀酰胆碱的指南。
Clin Pharmacol Ther. 2019 Jun;105(6):1338-1344. doi: 10.1002/cpt.1319. Epub 2019 Jan 24.
2
Malignant hyperthermia susceptibility: utilization of genetic results in an electronic medical record to increase safety.恶性高热易感性：利用电子病历中的遗传结果提高安全性。
Pharmacogenomics. 2020 Nov;21(17):1207-1215. doi: 10.2217/pgs-2020-0088. Epub 2020 Oct 29.
3
Pharmacogenetics and pathophysiology of CACNA1S mutations in malignant hyperthermia.恶性高热中CACNA1S基因突变的药物遗传学与病理生理学
Physiol Genomics. 2017 Feb 1;49(2):81-87. doi: 10.1152/physiolgenomics.00126.2016. Epub 2016 Dec 23.
4
Unexpected MH deaths without exposure to inhalation anesthetics in pediatric patients.儿科患者中未接触吸入麻醉剂却意外发生恶性高热死亡的情况。
Paediatr Anaesth. 2013 Sep;23(9):851-4. doi: 10.1111/pan.12224. Epub 2013 Jul 15.
5
PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics.药物基因组学知识库摘要：琥珀酰胆碱途径，药代动力学/药效学。
Pharmacogenet Genomics. 2015 Dec;25(12):622-30. doi: 10.1097/FPC.0000000000000170.
6
Volatile anesthetics and succinylcholine in cardiac ryanodine receptor defects.心脏兰尼碱受体缺陷中的挥发性麻醉剂和琥珀酰胆碱
Anesth Analg. 2004 Aug;99(2):435-7, table of contents. doi: 10.1213/01.ANE.0000130395.93107.15.
7
Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States.美国恶性高热易感人群中的 Ryanodine receptor type 1 基因变异。
Anesth Analg. 2013 May;116(5):1078-1086. doi: 10.1213/ANE.0b013e31828a71ff. Epub 2013 Apr 4.
8
Bayesian modeling to predict malignant hyperthermia susceptibility and pathogenicity of , and variants.贝叶斯建模预测 、 及 变异体恶性高热易感性和致病性。
Pharmacogenomics. 2019 Sep;20(14):989-1003. doi: 10.2217/pgs-2019-0055.
9
Using exome data to identify malignant hyperthermia susceptibility mutations.利用外显子组数据识别恶性高热易感性突变。
Anesthesiology. 2013 Nov;119(5):1043-53. doi: 10.1097/ALN.0b013e3182a8a8e7.
10
Updating probability of pathogenicity for RYR1 and CACNA1S exon variants in individuals without malignant hyperthermia after exposure to triggering anesthetics.暴露于触发麻醉剂后无恶性高热个体中RYR1和CACNA1S外显子变体致病性概率的更新
Pharmacogenet Genomics. 2025 Feb 1;35(2):65-72. doi: 10.1097/FPC.0000000000000551. Epub 2025 Jan 2.
引用本文的文献
1
Unveiling the heritability of selected unexplored pharmacogenetic markers in the Saudi population.揭示沙特人群中选定的未探索药物遗传标记的遗传力。
Front Pharmacol. 2025 May 1;16:1559399. doi: 10.3389/fphar.2025.1559399. eCollection 2025.
2
Genetic Variation and Sex-Based Differences: Current Considerations for Anesthetic Management.基因变异与基于性别的差异：麻醉管理的当前考量
Curr Issues Mol Biol. 2025 Mar 18;47(3):202. doi: 10.3390/cimb47030202.
3
Genetic variation in RYR1 is associated with heart failure progression and mortality in a diverse patient population.RYR1基因变异与不同患者群体的心力衰竭进展及死亡率相关。
Front Cardiovasc Med. 2025 Feb 21;12:1529114. doi: 10.3389/fcvm.2025.1529114. eCollection 2025.
4
Decoding Pharmacogenomic Test Interpretation and Application to Patient Care.解读药物基因组学检测结果及其在患者护理中的应用。
J Am Coll Clin Pharm. 2024 Jun;7(6):581-588. doi: 10.1002/jac5.1958. Epub 2024 May 8.
5
Pharmacogenetic analysis of structural variation in the 1000 genomes project using whole genome sequences.利用全基因组序列对 1000 基因组计划中的结构变异进行遗传药理学分析。
Sci Rep. 2024 Oct 1;14(1):22774. doi: 10.1038/s41598-024-73748-3.
6
Patterns of pharmacogenetic variation in nine biogeographic groups.九个生物地理群族中的药物遗传学变异模式。
Clin Transl Sci. 2024 Sep;17(9):e70017. doi: 10.1111/cts.70017.
7
Pharmacogenetics in Italy: current landscape and future prospects.意大利的药物遗传学：现状与未来展望。
Hum Genomics. 2024 Jul 10;18(1):78. doi: 10.1186/s40246-024-00612-w.
8
Personalized anesthesia and precision medicine: a comprehensive review of genetic factors, artificial intelligence, and patient-specific factors.个性化麻醉与精准医学：对遗传因素、人工智能及患者特异性因素的全面综述
Front Med (Lausanne). 2024 May 9;11:1365524. doi: 10.3389/fmed.2024.1365524. eCollection 2024.
9
Advancing pharmacogenetic testing in a tertiary hospital: a retrospective analysis after 10 years of activity.三级医院推进药物遗传学检测：10年活动后的回顾性分析
Front Pharmacol. 2023 Oct 19;14:1292416. doi: 10.3389/fphar.2023.1292416. eCollection 2023.
10
Implementation of Pharmacogenetics in First-Line Care: Evaluation of Its Use by General Practitioners.一线医疗中实施药物遗传学：全科医生对其应用的评估。
Genes (Basel). 2023 Sep 22;14(10):1841. doi: 10.3390/genes14101841.
本文引用的文献
1
Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.后基因组时代的恶性高热：旧概念的新视角
Anesthesiology. 2018 Jan;128(1):168-180. doi: 10.1097/ALN.0000000000001878.
2
Malignant Hyperthermia Susceptibility and Related Diseases.恶性高热易感性及相关疾病
Anesthesiology. 2018 Jan;128(1):159-167. doi: 10.1097/ALN.0000000000001877.
3
Identification of STAC3 variants in non-Native American families with overlapping features of Carey-Fineman-Ziter syndrome and Moebius syndrome.在具有凯里-费曼-齐特综合征和默比厄斯综合征重叠特征的非美洲原住民家庭中鉴定STAC3变异体。
Am J Med Genet A. 2017 Oct;173(10):2763-2771. doi: 10.1002/ajmg.a.38375. Epub 2017 Aug 4.
4
Pharmacogenomics in Anesthesia.麻醉中的药物基因组学
Anesthesiol Clin. 2017 Jun;35(2):285-294. doi: 10.1016/j.anclin.2017.01.014.
5
Novel STAC3 Mutations in the First Non-Amerindian Patient with Native American Myopathy.首例非美洲印第安人患美洲原住民肌病患者中的新型STAC3突变
Neuropediatrics. 2017 Dec;48(6):451-455. doi: 10.1055/s-0037-1601868. Epub 2017 Apr 15.
6
Genotype-Phenotype Correlations of Malignant Hyperthermia and Central Core Disease Mutations in the Central Region of the RYR1 Channel.RYR1通道中部区域恶性高热和中央轴空病突变的基因型-表型相关性
Hum Mutat. 2016 Nov;37(11):1231-1241. doi: 10.1002/humu.23072. Epub 2016 Sep 19.
7
Malignant hyperthermia: a review.恶性高热：综述
Orphanet J Rare Dis. 2015 Aug 4;10:93. doi: 10.1186/s13023-015-0310-1.
8
European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility.欧洲恶性高热症研究组恶性高热症易感性研究指南。
Br J Anaesth. 2015 Oct;115(4):531-9. doi: 10.1093/bja/aev225. Epub 2015 Jul 18.
9
RYR1-related myopathies: a wide spectrum of phenotypes throughout life.RYR1 相关性肌病：贯穿一生的广泛表型谱。
Eur J Neurol. 2015 Jul;22(7):1094-112. doi: 10.1111/ene.12713. Epub 2015 May 11.
10
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.临床药物遗传学实施联盟（CPIC）关于 G6PD 缺乏基因型下尿酸酶治疗的指南。
Clin Pharmacol Ther. 2014 Aug;96(2):169-74. doi: 10.1038/clpt.2014.97. Epub 2014 May 2.
Zotero 插件